Conservative treatment of mild-to-moderate ulcerative colitis
This publication provides information on ulcerative colitis (UC), including the definition, modern classifications (clinical and endoscopic), diagnostic algorithm and formulation of the diagnosis based on the 1CD-11 revision, which we began to use since 2022. The material consists of 2 groups: 1st -85 patients with UC of mild and moderate course, which were traced from the first attack (or exacerbation) with treatment with mesalazines (Mesacol®) to relief of exacerbation and transfer of patients to maintenance therapy. The 2nd group (conditionally “control” group) consisted of 15 patients with severe UC. This group, during dynamic monitoring, showed the development of severe complications, often requiring surgical treatment. It also confirms the thesis that diagnosis and treatment should be as early as possible, and maintenance therapy should be permanent. Another important statement arising from the presented material is that mesalazines in mild and moderate forms of the disease remain first-line treatment and maintenance therapy.